Brief: Cantargia Reports Positive Results For CAN10 Antibody In Preclinical Systemic Sclerosis Model
13/12/2021 12:02
Dec 13 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA REPORTS POSITIVE RESULTS FOR CAN10 ANTIBODY IN
PRECLINICAL SYSTEMIC SCLEROSIS MODEL
* LEVELS OF SEVERAL BIOMARKERS AFFECTED IN SYSTEMIC
SCLEROSIS
PATIENTS WERE NORMALIZED BY CAN10 IN THIS MODEL
* RESULTS SUPPORT CLINICAL DEVELOPMENT OF CAN10 IN SYSTEMIC
SCLEROSIS AND ARE TO BE PRESENTED AT A SCIENTIFIC CONFERENCE
DURING Q1 2022.
Source text for Eikon: ID:nWkr2KvXf8
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML